Compare Recursion Pharmaceuticals Inc (RXRX) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B), while Vanguard S&P 500 Growth Index Fund ETF trades at $81.95. The key difference: Vanguard S&P 500 Growth Index Fund ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | VOOG | |
|---|---|---|
Market Cap | $1.53B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $6.79 | $85.11 |
52-Week Low | $2.84 | $65.32 |
Enterprise Value | $946.50M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
VOOG (Vanguard S&P 500 Growth ETF) trades at $80.98, up 0.28% with a bearish technical signal from moving averages. The ETF provides exposure to 212 large-cap growth stocks with a 0.07% expense ratio and heavy technology sector concentration. Recent news highlights comparisons with other growth ETFs, noting VOOG's strong long-term performance and competitive fee structure.
The outlook remains cautious due to bearish technical indicators and concentrated tech exposure, though the low expense ratio and S&P 500 growth focus provide structural advantages. Key risks include tech sector volatility and market sentiment shifts, while institutional interest remains steady given Vanguard's reputation and the ETF's track record.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →
